Scotiabank raised its target from $558 to $660, citing Vertex's market position and growth prospects. This favorable analyst view supports Vertex, though it reports no new company results.
A higher target suggests Scotiabank sees more room for Vertex to grow. The story gives no new company results, so this is a favorable analyst view, not proof that sales or profits have improved.
Follow Vertex Pharmaceuticals (VRTX) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for VRTX